Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
The company is moving towards complex and more differentiated products
The company has operations in North America, Asia, and Europe,
Subscribe To Our Newsletter & Stay Updated
